Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
0000-00-00 | Ipsen (France) | nomination |
Nomination | |||
0000-00-00 | Santen Pharmaceutical (Japan) | new European Head Quarters in Geneva | opening of new premises |
Ophtalmological diseases | Opening of new premises | |
0000-00-00 | Bluebird bio (USA - MA) | resignation |
Resignation | |||
0000-00-00 | Ascendis Pharma (Denmark) | nomination |
Nomination | |||
0000-00-00 | Macrogenics (USA - MD) Synthon (The Netherlands) | MGC018, | licensing development |
Cancer - Oncology - Technology - Services | Licensing agreement | |
0000-00-00 | Macrogenics (USA - MD) Synthon (The Netherlands) | MGC018, | licensing development |
Cancer - Oncology - Technology - Services | Licensing agreement | |
0000-00-00 | Loxo Oncology (USA - CT) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) | companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib | Cancer - Oncology - Diagnostic | Establishment of a new subsidiary in the EU | ||
0000-00-00 | OSE Immunotherapeutics (France) Memorial Sloan Kettering Cancer Center (USA - NY) | OSE-703 (Effi-3) | solid tumors, non-small cell lung cancer (NSCLC) | research | Cancer - Oncology | Research agreement |
0000-00-00 | Race Oncology (Australia) TargImmune Therapeutics (Switzerland) Race Immunotherapeutics | bisantrene combined with TargImmune's targeted cancer therapy technology | joint-venture | Cancer - Oncology | Joint-venture agreement | |
0000-00-00 | vaccine manufacturing site in Val de Reuil | influenza | construction of new premises | Infectious diseases | Construction of new premises | |
0000-00-00 | Vectivbio (Switzerland) Asahi Kasei Pharma (Japan) | apraglutide | short bowel syndrome with intestinal failure (SBS-IF), acute graft-versus-host disease (aGVHD) | licensing | Inflammatory diseases - Gastrointestinal diseases - Transplantation | Licensing agreement |